New FDA Pulse Oximetry Guidance: Strengths and Weaknesses
The US Food and Drug Administration (FDA) issued new draft regulatory guidance for pulse oximeters related to skin pigment. The guidance is a step forward but it may have unintended consequences. Authors Michael Lipnick, MD, and Philip Bicker, MD, PhD, professors of anesthesia at University of California, San Francisco, discuss this and more with JAMA Executive Editor Gregory Curfman, MD.
Related Content:
Pulse Oximetry and Skin Pigmentation—New Guidance From the FDA
Adherence to FDA Guidance on Pulse Oximetry Testing Among Diverse Individuals, 1996-2024
Addressing Racial and Ethnic Bias in…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.